SeaStar Medical Holding (ICU) Return on Capital Employed (2021 - 2026)
SeaStar Medical Holding's (ICU) quarterly Return on Capital Employed came in at 136.42% in Q1 2026, up 59617.0% YoY from N/an in Q1 2025, and down 24.25% on a QoQ basis from 109.8% in Q4 2025.
SeaStar Medical Holding (ICU) Return on Capital Employed (2021 - 2026) Analysis & Trends
SeaStar Medical Holding (ICU) has 6 years of Return on Capital Employed data on file, last reported at 136.42% in Q1 2026.
- Quarterly Return on Capital Employed rose 59617.0% year-over-year to 136.42% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 136.42% (up 59617.0% YoY) and the FY2025 annual result came in at 214.08%, down 86656.0% from the prior year.
- Return on Capital Employed fell to 136.42% in Q1 2026, from 109.8% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 811.74% in Q4 2024 to a low of 732.59% in Q1 2025.
- A 5-year average of 71.87% and a median of 6.33% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 67014 bps — and 2025, when it slumped 107025 bps.
- Tracing ICU's Return on Capital Employed over 5 years: stood at 29.74% in 2022, then jumped by 576 bps to 141.6% in 2023, then surged by 473 bps to 811.74% in 2024, then sank by 114 bps to 109.8% in 2025, then slipped by 24 bps to 136.42% in 2026.
- The last three Return on Capital Employed figures came in at 136.42% (Q1 2026), 109.8% (Q4 2025), and 176.61% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | SeaStar Medical Holding | 13.68 Mn | 6.68 Mn | 561,000.00 | -248.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -248.85% |
| Mar 31, 2026 | -136.42% |
| Dec 31, 2025 | -109.80% |
| Sep 30, 2025 | -176.61% |
| Jun 30, 2025 | -236.51% |
| Mar 31, 2025 | -732.59% |
| Dec 31, 2024 | 811.74% |
| Sep 30, 2024 | 613.13% |
| Jun 30, 2024 | 335.10% |
| Mar 31, 2024 | 337.66% |
| Dec 31, 2023 | 141.60% |
| Sep 30, 2023 | 185.23% |
| Jun 30, 2023 | 158.65% |
| Mar 31, 2023 | 85.75% |
| Dec 31, 2022 | -29.74% |
| Sep 30, 2022 | -7.81% |
| Jun 30, 2022 | -6.33% |
| Mar 31, 2022 | -11.23% |
| Dec 31, 2021 | -8.85% |